Mark Picone is a Cardiology physician. OpenAlex indexes 12 publications with 783 citations (h-index 8).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
88.8%Statin28.2%Atorvastatin Calcium55%Rosuvastatin Calcium39%Pravastatin Sodium7%Part D<11 patientsBeta blocker17.3%Metoprolol Succinate50%Carvedilol38%Metoprolol Tartrate10%Atenolol3%Part D<11 patients+ 11 more classes in this area
Blood & clotting
9.9%P2Y12 inhibitor7.9%Clopidogrel78%Prasugrel Hcl22%Part D≥53 patientsFactor Xa inhibitor1.9%Eliquis56%Xarelto44%Part D<11 patientsMetabolism & gastrointestinal
1.4%Potassium supplement1.4%Potassium Chloride100%Part D≥14 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Ultrathin Bioresorbable Polymer Sirolimus-Eluting Stents in US Patients Undergoing Coronary Revascularization: 2-Year Outcomes From the BIOFLOW VII Trial
Journal of the Society for Cardiovascular Angiography & Interventions
2026 - Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation
European Heart Journal - Cardiovascular Pharmacotherapy
2024 - Ultrathin bioresorbable polymer sirolimus‐eluting stents in US patients undergoing coronary revascularization: 1‐Year outcomes from the BIOFLOW VII trial
Catheterization and Cardiovascular Interventions
2023 - Ultrathin Bioresorbable-Polymer Sirolimus-Eluting Stents in US Patients Undergoing Coronary Revascularization: 1-Year Outcomes From the BIOFLOW-VII Trial
Cardiovascular revascularization medicine
2023
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Deepak Bhatt, MD
Icahn School of Medicine at Mount Sinai
Harlan Krumholz, MD
Yale School of Medicine
Scott Solomon, MD
Brigham and Women's Hospital
Eric Topol, MD
Scripps Research Institute (Scripps Research)
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”